Cited by 339Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatmentAngiogenesis and VEGF in Cancer

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Wallace, Eli M., Rizzi, James P., Han, Guangzhou, Wehn, Paul M., Cao, Zhaodan, Du, Xinlin, Cheng, Tzuling, Czerwinski, Robert M., Dixon, Darryl D., Goggin, Barry S., Grina, Jonas A., Halfmann, Megan M., Maddie, Melissa A., Olive, Sarah R., Schlachter, Stephen T., Tan, Huiling, Wang, Bin, Wang, Keshi, Xie, Shanhai, Xu, Rui, Yang, Hanbiao, Josey, John A.·2016·Cancer Research

DOI 10.1158/0008-5472.can-16-0473

Published version of a preprint

Open this paper in CoChat — free account

Abstract

More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of the von Hippel–Lindau (pVHL) tumor suppressor, establishing it as the major underlying cause of this malignancy. pVHL inactivation results in stabilization of the hypoxia-inducible transcription factors, HIF1α and HIF2α, leading to expression of a genetic program essential for the initiation and progression of ccRCC. Herein, we describe the potent, selective, and orally active small-molecule inhibitor PT2385 as a specific antagonist of HIF2α that allosterically blocks its dimerization with the HIF1α/2α transcriptional dimerization partner ARNT/HIF1β. PT2385 inhibited the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts. Treatment of tumor-bearing mice with PT2385 caused dramatic tumor regressions, validating HIF2α as a pivotal oncogenic driver in ccRCC. Notably, unlike other anticancer agents that inhibit VEGF receptor signaling, PT2385 exhibited no adverse effect on cardiovascular performance. Thus, PT2385 represents a novel class of therapeutics for the treatment of RCC with potent preclincal efficacy as well as improved tolerability relative to current agents that target the VEGF pathway. Cancer Res; 76(18); 5491–500. ©2016 AACR.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-0473

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693

Show all 40 references

Sorted by citations

Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Self-citation
Hypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 626
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
Self-citation
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 418
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J. H., Zhou, J., & Zhang, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 388
Hypoxia signaling in human diseases and therapeutic targets
Lee, J. W., Ko, J., Ju, C., & Eltzschig, H. K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0235-1 · Cited by 384
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Self-citation
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N. G., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 365
Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis
Das, N. K., Schwartz, A. J., Barthel, G., Inohara, N., Liu, Q., Sankar, A., Hill, D. R., Ma, X., Lamberg, O., Schnizlein, M. K., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.005 · Cited by 331
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305
HIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies
Bai, R., Li, Y., Jian, L., Yue-hui, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 296
Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Zhao, Y., Xiong, W., Li, C., Zhao, R., Lu, H., Song, S., Zhou, Y., Hu, Y., Shi, B., & Ge, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01652-9 · Cited by 275
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α–mediated tumor progression
Liu, N., Luo, J., Kuang, D., Xu, S., Duan, Y., Xia, Y., Wei, Z., Xie, X., Yin, B., Chen, F., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123027 · Cited by 254
3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00719 · Cited by 220
Self-citation
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB
D’Ignazio, L., Batie, M., & Rocha, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020021 · Cited by 209
The von Hippel-Lindau Tumor Suppressor Gene
Elias, R. M., Zhang, Q. H., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 210
Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload
Schwartz, A. J., Das, N. K., Ramakrishnan, S. K., Jain, C., Jurkovic, M. T., Wu, J., Nemeth, E., Lakhal-Littleton, S., Colacino, J. A., & Shah, Y. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122359 · Cited by 203
Inherent DNA‐binding specificities of the HIF‐1α and HIF‐2α transcription factors in chromatin
Smythies, J. A., Sun, M., Masson, N., Salama, R., Simpson, P. D., Murray, E., Neumann, V., Cockman, M. E., Choudhry, H., Ratcliffe, P. J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201846401 · Cited by 195
HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188
Fluorine-containing drugs approved by the FDA in 2021
He, J., Li, Z., Dhawan, G., Zhang, W., Sorochinsky, A. E., Butler, G., Soloshonok, V. A., & Han, J. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.001 · Cited by 175
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 187
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 167
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 164
Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
Xie, C., Yagai, T., Luo, Y., Liang, X., Chen, T., Wang, Q., Sun, D., Zhao, J., Ramakrishnan, S. K., Sun, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4412 · Cited by 162
Hypoxia inducible factors in hepatocellular carcinoma
Chen, C., & Lou, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17358 · Cited by 159
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Shah, F., Logsdon, D. P., Messmann, R. A., Fehrenbacher, J. C., Fishel, M. L., & Kelley, M. R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0023-0 · Cited by 155
The Genomics and Genetics of Oxygen Homeostasis
Semenza, G. L. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111119-073356 · Cited by 141
HIF-2α is indispensable for regulatory T cell function
Hsu, T.-S., Lin, Y.-L., Wang, Y.-A., Mo, S.-T., Chi, P.-Y., Lai, A. C.-Y., Pan, H.-Y., Chang, Y.-J., & Lai, M.-Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18731-y · Cited by 126
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)
Wehn, P. M., Rizzi, J. P., Dixon, D. D., Grina, J. A., Schlachter, S. T., Wang, B., Xu, R., Yang, H., Du, X., Han, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01196 · Cited by 122
Self-citation
Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension
Hu, C., Poth, J. M., Zhang, H., Flockton, A. R., Laux, A., Kumar, S., McKeon, B. A., Mouradian, G. C., Li, M., Riddle, S. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00378-2019 · Cited by 121
Self-citation
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Li, T., Mao, C., Wang, X., Shi, Y., & Tao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01733-5 · Cited by 125
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
The role of hypoxia‐inducible factor‐2 alpha in angiogenesis
Befani, C. D., & Liakos, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26805 · Cited by 129
Bidirectional modulation of HIF-2 activity through chemical ligands
Wu, D., Su, X., Lu, J.-P., Li, S., Hood, B. L., Vasile, S., Potluri, N., Diao, X., Kim, Y., Khorasanizadeh, S., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0234-5 · Cited by 116
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Li, F., Aljahdali, I. A. M., Zhang, R., Nastiuk, K. L., Krolewski, J. J., & Ling, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02026-1 · Cited by 114
mRNA-to-protein translation in hypoxia
Chee, N. T., Lohse, I., & Brothers, S. P. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0968-4 · Cited by 115
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111
“For comparison, we tested the effect of PT2385, which inhibited EPO, NDRG1, ANGPTL4, and VEGFA expression but had no effect on CA9, which is consistent with its HIF-2–selective mechanism of action (44).”
MethodResult
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Martínez‐Sáez, O., Borau, P. G., Alonso‐Gordoa, T., Molina‐Cerrillo, J., & Grande, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.013 · Cited by 111
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics
Zhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 106
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
Kaelin, W. G. (2017) · Europe PMC (PubMed Central) · Cited by 111
The HIF and other quandaries in VHL disease
Tarade, D., & Ohh, M. (2017) · Oncogene · doi:10.1038/onc.2017.338 · Cited by 93
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Sun, X., Lv, X., Yan, Y., Zhao, Y., Ma, R., He, M., & Wei, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110623 · Cited by 93
Molecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 96
New insights into the links between hypoxia and iron homeostasis
Renassia, C., & Peyssonnaux, C. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000494 · Cited by 98
Best Practices for Constructing, Preparing, and Evaluating Protein-Ligand Binding Affinity Benchmarks [Article v1.0]
Hahn, D. F., Bayly, C. I., Boby, M. L., Macdonald, H. E. B., Chodera, J. D., Gapsys, V., Mey, A. S. J. S., Mobley, D. L., Pérez‐Benito, L., Schindler, C., et al. (2022) · Living Journal of Computational Molecular Science · doi:10.33011/livecoms.4.1.1497 · Cited by 103
PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity
Hu, W., Zheng, S., Guo, H., Dai, B., Ni, J., Shi, Y., Bian, H., Li, L., Shen, Y., Wu, M., et al. (2020) · Hepatology · doi:10.1002/hep.31293 · Cited by 86
Self-citation
Hypoxia and hypoxia-inducible factors in neuroblastoma
Påhlman, S., & Mohlin, S. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2701-1 · Cited by 85
Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions
Joshi, S. (2020) · Cancers · doi:10.3390/cancers12082057 · Cited by 86
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma
Liao, C., Hu, L., & Zhang, Q. H. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00876-w · Cited by 84
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Lai, Y., Zhao, Z., Zeng, T., Liang, X., Chen, D., Duan, X., Zeng, G., & Wu, W. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0530-2 · Cited by 81
NRF2 and Hypoxia-Inducible Factors: Key Players in the Redox Control of Systemic Iron Homeostasis
Duarte, T. L., Talbot, N. P., & Drakesmith, H. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8148 · Cited by 77
Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor
Dai, S., Qu, L., Li, J., Zhang, Y., Jiang, L., Wei, H., Guo, M., Chen, X., & Chen, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-33858-w · Cited by 76
Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer
Wu, Q., Tu, H., & Li, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.914730 · Cited by 68
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects
Shi, Y., & Gilkes, D. M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05537-0 · Cited by 81
A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis
Souza, R. F., Bayeh, L., Spechler, S. J., Tambar, U. K., & Bruick, R. K. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.10.004 · Cited by 66
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 68
Mechanisms governing target search and binding dynamics of hypoxia-inducible factors
Chen, Y., Cattoglio, C., Dailey, G. M., Zhu, Q., Tjian, R., & Darzacq, X. (2022) · eLife · doi:10.7554/elife.75064 · Cited by 60
Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications
Li, Z., You, Q., & Zhang, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01596 · Cited by 64
Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control
Cheng, X., Prange-Barczynska, M., Fielding, J. W., Zhang, M., Burrell, A. L., Lima, J. D. C. C., Eckardt, L., Argles, I. L. A., Pugh, C. W., Buckler, K. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133194 · Cited by 62
Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors
Neppala, P., Banerjee, S., Fanta, P. T., Yerba, M., Porras, K., Burgoyne, A. M., & Sicklick, J. K. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09818-0 · Cited by 61
Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome It
Mendoza, E. N., Ciriolo, M. R., & Ciccarone, F. (2025) · Antioxidants · doi:10.3390/antiox14010094 · Cited by 65
Time to target the circadian clock for drug discovery
Sjulstok, E., Takahashi, J. S., & Green, C. B. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.04.009 · Cited by 58
Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression
Westerlund, I., Shi, Y., Toskas, K., Fell, S. M., Li, S., Surova, O. V., Södersten, E., Kogner, P., Nyman, U., Schlisio, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700655114 · Cited by 58
Renal Cell Carcinoma: Molecular Aspects
Kumar, A., Kumari, N., Gupta, V., & Prasad, R. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0713-y · Cited by 64
Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma
Yu, Y.-C., Yu, Q., & Zhang, X. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.008 · Cited by 60
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72290-2 · Cited by 45
Hypoxia signaling: Challenges and opportunities for cancer therapy
Ivan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.002 · Cited by 57
Targeting HIF2 in Clear Cell Renal Cell CarcinomaPreprint
Cho, H., & Kaelin, W. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030833 · Cited by 60
Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma
Xie, H. J., Song, J. H., Godfrey, J. T., Riscal, R., Skuli, N., Nissim, I., & Simon, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00367-x · Cited by 56
Interactions between TGF-β type I receptor and hypoxia-inducible factor-α mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma
Mallikarjuna, P., Sitaram, R. T., Aripaka, K., Ljungberg, B., & Landström, M. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1642069 · Cited by 55
Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
Ikeda, H., & Kakeya, H. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00451-0 · Cited by 61
Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling
He, M., Yang, H., Shi, H., Hu, Y., Chang, C., Liu, S., & Yeh, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.028 · Cited by 54
Self-citation
A renal cell carcinoma tumorgraft platform to advance precision medicine
Elias, R. M., Tcheuyap, V. T., Kaushik, A., Singla, N., Gao, M., Reig, Ò., Christie, A. L., Mulgaonkar, A., Woolford, L., Stevens, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110055 · Cited by 61
Hypoxia, pseudohypoxia and cellular differentiation
Mohlin, S., Wigerup, C., Jögi, A., & Påhlman, S. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.007 · Cited by 54
The Cancer Clock Is (Not) Ticking: Links between Circadian Rhythms and Cancer
Morgan, M. N., Dvuchbabny, S., Martinez, C.-A., Kerr, B., Cistulli, P. A., & Cook, K. M. (2019) · Clocks & Sleep · doi:10.3390/clockssleep1040034 · Cited by 50
Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis
Zhang, M.-X., Zhang, L., Fu, L., Yao, H., Tan, L., Feng, Z., Li, J., Lu, J. K., Pan, Y., Shu, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01971-7 · Cited by 49
Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer
Zhao, C., Zeng, C., Ye, S., Dai, X., He, Q., Yang, B., & Zhu, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.010 · Cited by 49
Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme
Bou-Gharios, J., Noël, G., & Burckel, H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06904-2 · Cited by 51
Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma
Xiong, Y., Liu, L., Xia, Y., Qi, Y., Chen, Y., Chen, L., Zhang, P., Kong, Y., Qu, Y., Wang, Z., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02314-y · Cited by 48
MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness
Macharia, L. W., Muriithi, W., Mureithi, M., Pereira, C. M., Ferrer, V. P., & Moura‐Neto, V. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00125 · Cited by 46
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma
Hasanov, E., & Jonasch, E. W. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1925248 · Cited by 47
Role of Hypoxia and Metabolism in the Development of Neointimal Hyperplasia in Arteriovenous Fistulas
Sadaghianloo, N., Contenti, J., Dardik, A., & Mazure, N. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215387 · Cited by 45
HIF-1α Modulates Core Metabolism and Virus Replication in Primary Airway Epithelial Cells Infected with Respiratory Syncytial Virus
Morris, D. R., Qu, Y., Agrawal, A. S., Garofalo, R. P., & Casola, A. (2020) · Viruses · doi:10.3390/v12101088 · Cited by 45
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song, P., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q., & Jiang, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.586857 · Cited by 42
Hypoxia inducible factor (HIF) as a model for studying inhibition of protein–protein interactions
Burslem, G. M., Kyle, H. F., Nelson, A., Edwards, T. A., & Wilson, A. J. (2017) · Chemical Science · doi:10.1039/c7sc00388a · Cited by 39
Hypoxia-inducible factor 2α: a novel target in gliomas
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0163 · Cited by 40
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas
Toledo, R. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0479 · Cited by 42
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)
Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 40
ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma
Persson, C. U., von Stedingk, K., Fredlund, E., Bexell, D., Påhlman, S., Wigerup, C., & Mohlin, S. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111845 · Cited by 37
Targeting HIF-2α as therapy for advanced cancers
Murugesan, T., Rajajeyabalachandran, G., Kumar, S., Nagaraju, S., & Jegatheesan, S. K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.003 · Cited by 41
Targeting DNA binding proteins for cancer therapy
Shiroma, Y., Takahashi, R., Yamamoto, Y., & Tahara, H. (2020) · Cancer Science · doi:10.1111/cas.14355 · Cited by 39

Authors: Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., Grina, J. A., Halfmann, M. M., Maddie, M. A., Olive, S. R., Schlachter, S. T., Tan, H., Wang, B., Wang, K., Xie, S., Xu, R., Yang, H., & Josey, J. A.
Affiliations: Peloton Therapeutics, Inc., Dallas, Texas.
Corresponding author: Wallace, Eli M.
ORCID: Wallace, Eli M.
Han, Guangzhou
Wehn, Paul M.
Dixon, Darryl D.
Tan, Huiling
Wang, Bin
Wang, Keshi
Xu, Rui
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2016-09-15
Volume: 76
Issue: 18
Pages: 5491-5500
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-16-0473
OpenAlex: W2514212469
Cited by: 336
References: 40
Citations by year: 2026: 27 · 2025: 34 · 2024: 38 · 2023: 36 · 2022: 25 · 2021: 37 · 2020: 41 · 2019: 38 · 2018: 30 · 2017: 22 · 2016: 7
FWCI: 13.46
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords: HIF-2α, PT2385, clear cell renal cell carcinoma, small molecule inhibitors, hypoxia-inducible factor, VEGF-A, plasminogen activator inhibitor-1, cyclin D1, tumor xenografts, oral anticancer therapy, cardiovascular safety
MeSH terms: Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Calorimetry, Carcinoma, Renal Cell, Humans, Immunohistochemistry, Kidney Neoplasms, Polymerase Chain Reaction, Mice, SCID, Crystallography, X-Ray, Xenograft Model Antitumor Assays, Cell Line, Tumor, Immunoprecipitation, Mice, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks